A clinical study of using TEG to evaluate individualized protamine dosage on cardiac surgery under cardiopulmonary bypass

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052684

Enrollment

Unknown

Registered

2021-11-03

Start date

2021-12-12

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart valve disease

Interventions

Experimental group:Dosing according to heparin sensitivity

Control group:Routine dosing

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Hospitalized patients undergoing elective valve replacement surgery under cardiopulmonary bypass in this medical institution.

Exclusion criteria

Exclusion criteria: 1. Emergency surgery; 2. Aged 20 mmol/L, INR > 2.0); 6. Definite renal impairment (GFR < 30 ml/min/1.73 m2).

Design outcomes

Primary

Measure	Time frame
Protamine dose;Heparin residual rate;Chest tube drainage 24 hours postoperatively;	—

Secondary

Measure	Time frame
Postoperative mechanical ventilation time;blood transfusion volume;Routine coagulation indicators;cardiovascular and cerebrovascular events;death rate;	—

Countries

China

Contacts

Public ContactDai Zeping

Yijishan Hospital of Wannan Medical College

zpdai@wnmc.edu.cn+86 13955365823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026